Clinical trialObservationalEnrolling by invitation
A Study on Multimodal Prognostic Scoring of Advanced PDAC.
A Multimodal Prognostic Model for Advanced Pancreatic Ductal Adenocarcinoma Patients: a Retrospective and Prospective, Observational, Multicenter Study.
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Enrolling by invitation
- Study type
- Observational
- Start
- 2 March 2025
- Expected end
- 1 March 2027
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- Overall survival (OS)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 28 January 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to construct unimodal and multimodal prediction models for overall survival (OS), progression free survival (PFS), and treatment response (complete response+partial response) of advanced first-line chemotherapy based on the imaging, pathological, and genomic characteristics of patients, and evaluate their predictive efficacy.